Today is the third annual World Head & Neck Cancer Day, a day that brings together physicians, patients and policy makers to raise awareness about the disease and recent treatment advances.
Head and neck cancers will account for nearly 65,000 new cancer cases diagnosed in the United States this year, causing over an estimated 13,000 deaths, according to the American Cancer Society.
In honor of World Head & Neck Cancer Day, HemOnc Today compiled a list of six updates in the field of head and neck cancer, including new research on immunotherapy agents and symptom monitoring strategies.
- Immunotherapy agents have had a dramatic impact on a variety of cancer types, including head and neck cancer. Two researchers discuss this “paradigm-shifting” treatment. READ MORE.
- Neoadjuvant chemotherapy and surgery followed by risk-adapted adjuvant therapy produced “excellent” outcomes among patients with head and neck squamous cell carcinoma. READ MORE.
- Women appeared less likely than men to receive intensive treatment for head and neck cancer. When researchers controlled for factors such as age and serious medical conditions, their analysis showed the ratio of cancer mortality to noncancer mortality was twice as high among women than men. READ MORE.
- Patients with head and neck cancer who underwent remote monitoring by a mobile app and sensor technology had less severe symptoms than patients who had weekly doctor visits. READ MORE.
- The median age of patients with HPV-related oropharyngeal squamous cell carcinoma increased since 1995, reflecting the increasing incidence among older adults. Regardless of age, patients with HPV-related oropharyngeal squamous cell carcinoma demonstrated improved OS compared with patients with HPV-unrelated tumors. READ MORE.
- Researchers at Atlantic HPV Center at Leonard B. Kahn Head and Neck Cancer Institute are studying an experimental HPV vaccine and treatment with the PD-L1 inhibitor durvalumab (Imfinzi, AstraZeneca) in a cohort of patients with HPV-associated head and neck cancers. READ MORE.